February 5, 2018 05:58 PM EST
R&D

Roche hails an­oth­er PhI­II win on Tecen­triq com­bo, re­ports promis­ing kid­ney can­cer da­ta

Brittany Meiling

Roche is ped­al­ing hard from be­hind in the race for PD-1/L1 mar­ket su­prema­cy, an­nounc­ing news at mar­ket close Mon­day that it’s wrapped up yet an­oth­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times